Last Updated: November 17, 2026

Claims for Patent: 12,054,498

« Back to Dashboard


Summary for Patent: 12,054,498
Title:Heteroaromatic macrocyclic ether chemotherapeutic agents
Abstract:Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds of Formula (I): pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The disclosure further relates to methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof.
Inventor(s):Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
Assignee: Pharmaresources Co Ltd , Nuvalent Inc
Application Number:US17/834,135
Patent Claims: 1. A method for treating cancer in a subject, wherein the method comprises administering to the subject in need thereof a therapeutically effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt, enantiomer, or tautomer thereof, wherein: Q is CH; Z is CR5; X is: wherein: * indicates the point of attachment of X to the —CH2— group bonded to Y; Y is: wherein: * indicates the point of attachment of Y to the —CH2— group bonded to X; R1 is H, CH3, or CH2OH; each R2 is independently H, halo, C1-4 alkyl, C1-4 haloalkyl, CH2-C3-4 cycloalkyl, OC1-4 alkyl, C3-6 cycloalkyl, or three- to six-membered heterocycloalkyl; each R3 is H, halo, CN, C1-4 alkyl, C1-4 haloalkyl, or OC1-4 alkyl; R4 is H or F; and R5 is H or F.

2. A method for treating cancer in a subject, wherein the method comprises administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier or excipient, and (ii) a compound of Formula (I): or a pharmaceutically acceptable salt, enantiomer, or tautomer thereof, wherein: Q is CH; Z is CR5; X is: wherein: *indicates the point of attachment of X to the —CH2— group bonded to Y; Y is: wherein: * indicates the point of attachment of Y to the —CH2— group bonded to X; R1 is H, CH3, or CH2OH; each R2 is independently H, halo, C1-4 alkyl, C1-4 haloalkyl, CH2—C3-4 cycloalkyl, OC1-4 alkyl, C3-6 cycloalkyl, or three- to six-membered heterocycloalkyl; each R3 is H, halo, CN, C1-4 alkyl, C1-4 haloalkyl, or OC1-4 alkyl; R4 is H or F; and R5 is H or F.

3. A method for treating cancer in a subject, wherein the method comprises administering to the subject in need thereof a therapeutically effective amount of a compound of Formula (I-B): or a pharmaceutically acceptable salt thereof, wherein: Q is CH; Z is CR5; X is: wherein: *indicates the point of attachment of X to the —CH2— group bonded to Y; Y is: wherein: * indicates the point of attachment of Y to the —CH2— group bonded to X; R1 is H, CH3, or CH2OH; each R2 is independently H, halo, C1-4 alkyl, C1-4 haloalkyl, CH2—C3-4 cycloalkyl, OC1-4 alkyl, C3-6 cycloalkyl, or three- to six-membered heterocycloalkyl; each R3 is H, halo, CN, C1-4 alkyl, C1-4 haloalkyl, or OC1-4 alkyl; R4 is H or F; and R5 is H or F.

4. The method of claim 3, wherein the cancer is an anaplastic lymphoma kinase (ALK) positive cancer.

5. The method of claim 4, wherein the ALK positive cancer has a G1202R mutation.

6. The method of claim 3, wherein the cancer is a ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) positive cancer.

7. The method of claim 6, wherein the ROS1 positive cancer has a G2032R mutation.

8. The method of claim 3, wherein the cancer is selected from the group consisting of angiosarcoma, bile duct cancer, breast cancer, colon cancer, colorectal cancer, epithelioid hemangioendothelioma, esophageal cancer, gastric cancer, glioblastoma, an inflammatory myofibroblastic tumor (IMT), kidney cancer, lung cancer, melanoma, neuroblastoma, ovarian cancer, a spitzoid tumor, and thyroid cancer.

9. The method of claim 8, wherein the cancer is lung cancer.

10. The method of claim 9, wherein the lung cancer is non-small cell lung cancer.

11. The method of claim 3, wherein the cancer is a solid tumor.

12. The method of claim 3, wherein each R2 is independently H, Cl, CH3, CH2CH3, CH2CH(CH3)2, CHF2, CF3, CH2CH2F, CH2CHF2, CH2-cyclopropyl, OCH3, cyclopropyl, cyclobutyl, or oxetanyl.

13. The method of claim 12, wherein each R3 is H, F, Cl, CN, CH3, or CH2CH3.

14. The method of claim 13, wherein R4 is F.

15. The method of claim 14, wherein R5 is H.

16. The method of claim 3, wherein the compound is: or a pharmaceutically acceptable salt thereof.

17. The method of claim 3, wherein the compound is: or a pharmaceutically acceptable salt thereof.

18. The method of claim 3, wherein the compound is: or a pharmaceutically acceptable salt thereof.

19. The method of claim 3, wherein the compound is: or a pharmaceutically acceptable salt thereof.

20. The method of claim 3, wherein the compound is: or a pharmaceutically acceptable salt thereof.

21. The method of claim 3, wherein the compound is: or a pharmaceutically acceptable salt thereof.

22. The method of claim 3, wherein the compound is: or a pharmaceutically acceptable salt thereof.

23. The method of claim 3, wherein the compound is: or a pharmaceutically acceptable salt thereof.

24. The method of claim 3, wherein the compound is: or a pharmaceutically acceptable salt thereof.

25. The method of claim 3, wherein the compound is: or a pharmaceutically acceptable salt thereof.

26. The method of claim 3, wherein the compound is: or a pharmaceutically acceptable salt thereof.

27. The method of claim 3, wherein the compound is: or a pharmaceutically acceptable salt thereof.

28. A method for treating cancer in a subject, wherein the method comprises administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier or excipient, and (ii) a compound of Formula (I-B): or a pharmaceutically acceptable salt thereof, wherein: Q is CH; Z is CR5; X is: wherein: *indicates the point of attachment of X to the —CH2— group bonded to Y; Y is: wherein: * indicates the point of attachment of Y to the —CH2— group bonded to X; R1 is H, CH3, or CH2OH; each R2 is independently H, halo, C1-4 alkyl, C1-4 haloalkyl, CH2—C3-4 cycloalkyl, OC1-4 alkyl, C3-6 cycloalkyl, or three- to six-membered heterocycloalkyl; each R3 is H, halo, CN, C1-4 alkyl, C1-4 haloalkyl, or OC1-4 alkyl; R4 is H or F; and R5 is H or F.

29. The method of claim 28, wherein the cancer is an anaplastic lymphoma kinase (ALK) positive cancer.

30. The method of claim 29, wherein the ALK positive cancer has a G1202R mutation.

31. The method of claim 28, wherein the cancer is a ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) positive cancer.

32. The method of claim 31, wherein the ROS1 positive cancer has a G2032R mutation.

33. The method of claim 28, wherein the cancer is selected from the group consisting of angiosarcoma, bile duct cancer, breast cancer, colon cancer, colorectal cancer, epithelioid hemangioendothelioma, esophageal cancer, gastric cancer, glioblastoma, an inflammatory myofibroblastic tumor (IMT), kidney cancer, lung cancer, melanoma, neuroblastoma, ovarian cancer, a spitzoid tumor, and thyroid cancer.

34. The method of claim 33, wherein the cancer is lung cancer.

35. The method of claim 34, wherein the lung cancer is non-small cell lung cancer.

36. The method of claim 28, wherein the cancer is a solid tumor.

37. The method of claim 28, wherein the compound is: or a pharmaceutically acceptable salt thereof.

38. The method of claim 28, wherein the compound is: or a pharmaceutically acceptable salt thereof.

39. The method of claim 28, wherein the compound is: or a pharmaceutically acceptable salt thereof.

40. The method of claim 28, wherein the compound is: or a pharmaceutically acceptable salt thereof.

41. The method of claim 28, wherein the compound is: or a pharmaceutically acceptable salt thereof.

42. The method of claim 28, wherein the compound is: or a pharmaceutically acceptable salt thereof.

43. The method of claim 28, wherein the compound is: or a pharmaceutically acceptable salt thereof.

44. The method of claim 28, wherein the compound is: or a pharmaceutically acceptable salt thereof.

45. The method of claim 28, wherein the compound is: or a pharmaceutically acceptable salt thereof.

46. The method of claim 28, wherein the compound is: or a pharmaceutically acceptable salt thereof.

47. The method of claim 28, wherein the compound is: or a pharmaceutically acceptable salt thereof.

48. The method of claim 28, wherein the compound is: or a pharmaceutically acceptable salt thereof.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.